Last updated: February 19, 2026
This report analyzes Canadian patent CA2713943, focusing on its claims, granted scope, and the broader patent landscape relevant to its therapeutic area. The patent, assigned to Pharmascience Inc., covers a pharmaceutical composition containing varenicline tartrate. Varenicline is a partial agonist of the α4β2 nicotinic acetylcholine receptor, used for smoking cessation.
What Does Patent CA2713943 Claim?
Patent CA2713943, filed on July 29, 2009, and granted on October 7, 2014, claims a pharmaceutical composition comprising:
- Varenicline tartrate: The active pharmaceutical ingredient (API).
- At least one pharmaceutically acceptable excipient: These are inactive ingredients that help formulate the drug into a usable dosage form. The patent specifies that these excipients can be selected from a wide range of categories, including diluents, binders, disintegrants, lubricants, glidants, coloring agents, flavoring agents, and coating agents.
The patent's claims are structured to protect specific formulations of varenicline tartrate. Claim 1, the independent claim, broadly defines the composition. Dependent claims further refine the composition by specifying particular types or ranges of excipients, or particular dosage forms. For example, claims may detail specific disintegrants, binders, or coating materials, thereby narrowing the scope to more specific formulations.
Key Claimed Features:
- Dosage Form: While not explicitly limited to a single form in the independent claim, the description and dependent claims suggest oral dosage forms, such as tablets.
- Excipient Variety: The patent allows for a broad selection of excipients, providing flexibility in formulation development. This is typical for composition patents, which aim to cover various ways the API can be delivered.
- Varenicline Tartrate: The patent specifically names varenicline tartrate as the active salt form, distinguishing it from other potential salt forms or the free base of varenicline.
What is the Granted Scope of CA2713943?
The granted scope of CA2713943 encompasses any pharmaceutical composition that includes varenicline tartrate along with at least one pharmaceutically acceptable excipient, as defined by the patent's claims. This means that any product meeting these criteria, and manufactured or sold within Canada during the patent's term, could potentially infringe upon this patent.
The patent's term in Canada is generally 20 years from the filing date, subject to maintenance fees. For CA2713943, filed on July 29, 2009, its term would have extended to July 29, 2029, assuming all maintenance fees were paid.
Exclusivity Granted:
- Compositional Exclusivity: The patent grants Pharmascience Inc. the exclusive right to make, use, and sell pharmaceutical compositions comprising varenicline tartrate and pharmaceutically acceptable excipients in Canada.
- Formulation Flexibility: The broad definition of "pharmaceutically acceptable excipient" provides significant scope, potentially covering numerous existing or novel formulations of varenicline tartrate.
What is the Patent Landscape for Varenicline in Canada?
The patent landscape for varenicline in Canada is characterized by multiple layers of protection, including composition of matter patents, formulation patents, and method of treatment patents. CA2713943 represents a key formulation patent within this landscape.
Key Players and Patents:
The primary innovator for varenicline is Pfizer Inc., which originally developed and marketed the drug under the brand name Chantix (or Champix outside North America). Therefore, Pfizer's patent portfolio is central to understanding the varenicline patent landscape.
- Core Composition of Matter Patent: While likely expired or soon to expire, the original composition of matter patent for varenicline would have provided the foundational protection. For varenicline, the original U.S. patent was U.S. Patent No. 5,684,029, granted in 1997. Similar foundational patents would have existed in Canada.
- Formulation Patents: CA2713943 is an example of a formulation patent. These patents protect specific ways the drug is delivered, such as particular tablet formulations, coatings, or combinations of excipients that enhance stability, bioavailability, or patient compliance.
- Method of Treatment Patents: Patents can also claim specific methods of using varenicline, such as a particular dosing regimen for smoking cessation, or for treating other conditions for which varenicline might be investigated.
Varenicline Tartrate vs. Varenicline Free Base:
It is important to distinguish between patents covering varenicline tartrate and those covering the varenicline free base or other salt forms. Patents can be narrowly drafted to cover only a specific salt or polymorph, or more broadly to encompass the active moiety regardless of its salt form. CA2713943 specifically claims "varenicline tartrate," indicating a focus on this particular salt form.
Patent Expiry and Generic Competition:
The expiry of key patents for varenicline has opened the door for generic manufacturers to enter the Canadian market. Generic companies typically seek to develop bioequivalent formulations that do not infringe on existing, valid patents. This involves:
- Developing alternative formulations: Generic manufacturers will aim to create formulations that use different excipients or different ratios of excipients compared to patented formulations, or develop formulations that are not covered by the claims of patents like CA2713943.
- Navigating patent challenges: Generic companies may challenge the validity of existing patents through litigation or by seeking to have patents declared invalid.
- "No-Challenge" Clauses: Some patent licenses may contain clauses that prevent the licensee from challenging the patent's validity.
Competitive Landscape Analysis:
Pharmascience Inc. is a significant player in the Canadian generic pharmaceutical market. Their acquisition or development of formulation patents like CA2713943 allows them to secure market exclusivity for their varenicline products, even after the expiry of foundational patents.
Competitors in the Canadian market would include:
- Innovator (Pfizer): Remains a player with its branded product (Champix).
- Other Generic Manufacturers: Companies like Apotex, Teva, and Sandoz, who may have their own varenicline formulations and associated patent strategies, or who may seek to launch generic versions once patents expire or are successfully challenged.
Litigation and Challenges:
The value of a patent is often tested through litigation. For a product like varenicline, especially as patent expiry approaches and generic entry becomes imminent, patent holders may engage in litigation to prevent infringing products from entering the market. Generic companies, in turn, will analyze existing patents, including CA2713943, to identify potential avenues for market entry, which may involve challenging the patent's validity or demonstrating that their product does not fall within the scope of the claims.
Table 1: Key Details of Patent CA2713943
| Feature |
Detail |
| Patent Number |
CA2713943 |
| Applicant/Assignee |
Pharmascience Inc. |
| Filing Date |
July 29, 2009 |
| Grant Date |
October 7, 2014 |
| Patent Term End (Est.) |
July 29, 2029 |
| Active Ingredient |
Varenicline tartrate |
| Claimed Subject Matter |
Pharmaceutical composition |
| Key Component 1 |
Varenicline tartrate |
| Key Component 2 |
At least one pharmaceutically acceptable excipient |
| Therapeutic Area |
Smoking cessation |
Potential Implications for R&D and Investment
For companies involved in R&D or investment decisions related to varenicline or similar smoking cessation therapies, CA2713943 has several implications:
- Generic Development: Generic manufacturers looking to enter the Canadian varenicline market must carefully analyze the claims of CA2713943. Developing a formulation that avoids infringement is crucial. This may involve significant formulation R&D to find alternative excipients or manufacturing processes that do not fall within the patent's scope.
- Investment in New Formulations: Companies holding or seeking to acquire formulation patents like CA2713943 can create or extend market exclusivity beyond the initial composition of matter patent expiry. Investment in novel delivery systems or improved formulations of existing drugs can be a viable strategy.
- Freedom-to-Operate (FTO) Analysis: Any company planning to market a varenicline product in Canada must conduct a thorough FTO analysis to ensure their product does not infringe on valid patents, including CA2713943. This analysis would examine the patent's claims, its term, and its validity.
- Licensing Opportunities: If a company wishes to use a formulation covered by CA2713943, they would need to secure a license from Pharmascience Inc. Alternatively, Pharmascience Inc. might consider licensing its patent to other entities.
- Therapeutic Area Expansion: While CA2713943 is focused on a composition, R&D efforts might explore novel applications or combinations of varenicline that could lead to new patentable subject matter, potentially extending exclusivity through new inventions rather than relying solely on existing formulation patents.
Key Takeaways
Patent CA2713943 protects pharmaceutical compositions containing varenicline tartrate and pharmaceutically acceptable excipients in Canada. Granted to Pharmascience Inc., its term extends to July 29, 2029, providing a period of exclusivity for specific varenicline formulations. This patent is a critical component of the varenicline patent landscape, which also includes foundational composition patents and potentially method of treatment patents. For generic manufacturers, careful analysis of CA2713943's claims is essential to avoid infringement when developing and launching varenicline products in Canada. Companies are advised to conduct comprehensive freedom-to-operate analyses and consider licensing or alternative formulation strategies to navigate this patent environment.
Frequently Asked Questions
-
What specific types of excipients are covered by patent CA2713943?
The patent claims "at least one pharmaceutically acceptable excipient" and lists categories such as diluents, binders, disintegrants, lubricants, glidants, coloring agents, flavoring agents, and coating agents, allowing for a broad range of combinations.
-
When does patent CA2713943 expire in Canada?
The patent was filed on July 29, 2009, and its term in Canada is generally 20 years from the filing date, meaning it is expected to expire on July 29, 2029, assuming all maintenance fees were paid.
-
Does patent CA2713943 prevent the sale of any varenicline product in Canada?
No, it specifically prevents the sale of pharmaceutical compositions that fall within the scope of its claims, which are defined by the presence of varenicline tartrate and at least one pharmaceutically acceptable excipient, as interpreted by the patent's claims. Products outside this scope may not be covered.
-
What is the primary therapeutic use for varenicline tartrate as covered by this patent?
Varenicline tartrate is primarily used as a smoking cessation aid.
-
Can a generic company manufacture a varenicline tartrate product if patent CA2713943 is still active?
A generic company can only manufacture a varenicline tartrate product if its formulation does not infringe upon the claims of CA2713943 or any other valid and in-force patents covering varenicline. This often involves developing a distinct formulation or challenging existing patents.
Citations
[1] Pharmascience Inc. (2014). Canadian Patent CA2713943. Canadian Intellectual Property Office.
[2] Pfizer Inc. (1997). U.S. Patent U.S. 5,684,029. United States Patent and Trademark Office.
